Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.61 |
| ▸ | BCL2 | P10415 | 4/20 | 0.58 |
| ▸ | CTSS | P25774 | 9/20 | 0.55 |
| ▸ | CTSK | P43235 | 7/20 | 0.55 |
| ▸ | CTSB | P07858 | 3/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.47 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.47 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.47 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4927242 | 1.00 | PTPN1 (0.61) | PTPN1BCL2CTSSCTSKCTSB | |
| SCHEMBL4935642 | 0.91 | BCL2 (0.60) | PTPN1BCL2CTSSCTSKCTSB | |
| SCHEMBL4935633 | 0.91 | BCL2 (0.60) | PTPN1BCL2CTSSCTSKCTSB | |
| SCHEMBL4934994 | 0.87 | BCL2 (0.56) | PTPN1BCL2CTSSCTSKCTSB | |
| SCHEMBL4934981 | 0.87 | BCL2 (0.56) | PTPN1BCL2CTSSCTSKCTSB | |
| SCHEMBL4937234 | 0.85 | HDAC8 (0.55) | PTPN1BCL2CTSSCTSKCTSB | |
| SCHEMBL4937247 | 0.85 | HDAC8 (0.55) | PTPN1BCL2CTSSCTSKCTSB | |
| SCHEMBL4934824 | 0.85 | PTPN1 (0.56) | PTPN1BCL2CTSSCTSKCTSB | |
| SCHEMBL4934829 | 0.85 | PTPN1 (0.56) | PTPN1BCL2CTSSCTSKCTSB | |
| SCHEMBL4934295 | 0.82 | PTPN1 (0.56) | PTPN1BCL2CTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | KUREHA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1707560-A1 | HYDROXAMIC ACID DERIVATIVE AND AGE GENERATION INHIBITOR CONTAINING THE DERIVATIVE | Kureha Corporation (JP) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | HDAC5, HDAC1, HDAC9 | PTPN1 3437/4885BCL2 3483/4885CTSS 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.